TEVATeva Pharmaceutical Industries Limited

1. Sep 16, 2026On September 16, 2026, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “Company”), issued €1,000,000,000 aggregate principal amount of 4.250% Senior Notes due 2033 (the “2033 Euro Notes”) and €500,000,000 aggregate …Material agreement entered · Form 8-K
2. Sep 14, 2026On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the ADSs previously traded, “TEVA”Other event · Form 8-K
3. Sep 11, 2026On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”), Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”), Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and together with Teva Finance II and Teva Finance III, the “Issuers”) and, the Company …Regulation FD disclosure · Form 8-K
4. Sep 3, 2026Teva Pharmaceutical Industries Limited (the “Company”) is filing this Current Report on Form 8-K to recast historical segment information as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 3, 2026 (the …Other event · Form 8-K
5. Sep 3, 2026On August 31, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) executed an amendment (such amendment, the “Amendment No. 1”) to the Second Amended and restated Deposit Agreement, dated as of December 4, 2018, among the Company, Citibank, N.A., as depositary (the “Depositary”) and all holders and beneficial …Shareholder rights modified · Form 8-K
6. Jul 29, 2026Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting.Earnings release · press release
7. Apr 29, 2026Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution.Earnings release · press release
8. Jan 28, 2026Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive.Earnings release · press release
9. Jan 12, 2026Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation.Earnings release · press release
10. Dec 11, 2025Amendment to Revolving Credit Agreement On December 10, 2025, Teva Pharmaceutical Industries Limited (the “Company”) obtained the consent of each of the lenders (the “Lenders”) party to its Revolving Facility Agreement (as defined below) to extend the stated maturity date of the commitments and loans thereunder from …Material agreement entered · Form 8-K
11. Nov 5, 2025Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.